Panobinostat Lactate

乳酸帕比司他

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NamePanobinostat Lactate
Drug Alias Namepanobinostat帕比司他乳酸盐帕比司他FarydakLBH-589B +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitors
TargetsHistone deacetylase
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerHormone-Resistant Prostate Neoplasms +[70] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/02/23
Country/TerritoryCzechiaBelgiumCanada +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesGHN Pharma Nordic ABNovartis Pharma AgNational Cancer Institute +[4] 
Inactive CompaniesDana-Farber Cancer InstituteUniversity Of California San FranciscoThe University Of California Davis +[31] 
Active IndicationsMultiple MyelomaGlioma
Inactive IndicationsBrain metastasesMetastatic breast cancerHormone-Resistant Prostate Neoplasms +[68] 

Other Information

ATC CodeL01XH03
Related LinksWikipediaDrugBankKEGG